4 pmprb webinar recommendations louise binder april 7 2020
•Download as PPTX, PDF•
0 likes•70 views
The Patients Redefining Healthcare Summit co-hosts, in partnership with the Indigenous Advisory Committee, invite you to join us as we discuss six case studies of oncology drugs analyzed by a health economist based on the proposed PMPRB guidelines. The results and the implications for accessing drugs will be presented. Potential application of this analytical approach in non-oncology areas will also be discussed. Webinar recording available on Save Your Skin Foundation youTube channel.
Report
Share
Report
Share
Recommended
1 pmprb webinar april 7 2020 wayne critchley
This document summarizes a webinar about proposed reforms to the Patented Medicine Prices Review Board (PMPRB) in Canada. The key points are:
1) The PMPRB regulates drug prices to ensure they are not excessive but reforms aim to make it more "relevant" and lower prices by 20%.
2) New proposals would expand the international drug price comparator countries to include lower-cost nations and add new "economic" pricing factors.
3) There is concern the reforms could discourage drug launches in Canada and clinical trials due to greater price uncertainty and the risk of much lower allowed prices.
emaxians
This document proposes solutions to improve the reach and efficiency of India's Public Distribution System. It identifies key issues like inadequate coverage of the poor, lack of monitoring and technology use, and corruption. The proposed solutions include defining new poverty indicators, direct collection and distribution of grains, using smart cards and biometric authentication. This would introduce transparency, reduce leakage, and ensure fair access to subsidies. The solutions could be implemented nationwide and sustained through centralized data collection and regular audits with cooperation between central and state governments.
2 chart - hta and pmprb comparison april 7 2020 webinar
Chart created by: Louise Binder & Antonella Scali
The Patients Redefining Healthcare Summit co-hosts, in partnership with the Indigenous Advisory Committee, invite you to join us as we discuss six case studies of oncology drugs analyzed by a health economist based on the proposed PMPRB guidelines. The results and the implications for accessing drugs will be presented. Potential application of this analytical approach in non-oncology areas will also be discussed.
Changing Regulatory Landscape of 2017
In MakroCare whitepaper, we have compiled and simplified some of these new policies, revisions, regulatory amendments from registration, labeling, safety reporting, renewal, publishing /eCTD submission of last year and forthcoming years.
WHO Contribution to impementing MeTA
The role of the World Health Organization (WHO) in the Medicines Transparency Alliance (MeTA), May 2008
PharmacoVigilance Newsletter
Lanzule Limited provides pharmacovigilance services including adverse incident reporting for drugs, devices, and combination products. As of July 2nd 2015, marketing authorization holders must have a Pharmacovigilance System Master File in place to document their pharmacovigilance system and compliance. This applies to products authorized through centralized or non-centralized procedures. Manufacturers of medical devices and mobile medical apps must also have a vigilance system. Lanzule can help collect safety information and report adverse drug reactions electronically or on paper to regulatory authorities.
Background to the Falsified Medicines Directive and the Delegated Regulation
The document discusses the Falsified Medicines Directive and Delegated Regulation, which aim to secure the pharmaceutical supply chain and reduce counterfeit medicines. It outlines key aspects of the new regulations, including unique identifiers and tamper-evident packaging for prescription medicines. Verification of authenticity will occur at wholesale distributors and dispensing points. National repositories will store product information to enable verification. Implementation poses scale and connectivity challenges across the complex supply chain. Wider benefits may include improved patient safety, monitoring, and reducing fraud. Flexibilities allow country-specific requirements and earlier verification in some settings like hospitals.
Former government proposed models
The document outlines several past and proposed models for a national pharmacare program in Canada, including:
1. The 2003 First Ministers Health Accord and National Pharmaceuticals Strategy proposed universal coverage with two options for income-based cost sharing thresholds but negotiations failed.
2. The 2002 Kirby and Romanow reports recommended a $1500 annual catastrophic drug coverage threshold but their recommendations did not move forward.
3. The 2009 Canadian Treatment Action Council model proposed a universal catastrophic drug plan with income-based cost sharing, centralized management, and funding from governments, employers, and manufacturers.
Recommended
1 pmprb webinar april 7 2020 wayne critchley
This document summarizes a webinar about proposed reforms to the Patented Medicine Prices Review Board (PMPRB) in Canada. The key points are:
1) The PMPRB regulates drug prices to ensure they are not excessive but reforms aim to make it more "relevant" and lower prices by 20%.
2) New proposals would expand the international drug price comparator countries to include lower-cost nations and add new "economic" pricing factors.
3) There is concern the reforms could discourage drug launches in Canada and clinical trials due to greater price uncertainty and the risk of much lower allowed prices.
emaxians
This document proposes solutions to improve the reach and efficiency of India's Public Distribution System. It identifies key issues like inadequate coverage of the poor, lack of monitoring and technology use, and corruption. The proposed solutions include defining new poverty indicators, direct collection and distribution of grains, using smart cards and biometric authentication. This would introduce transparency, reduce leakage, and ensure fair access to subsidies. The solutions could be implemented nationwide and sustained through centralized data collection and regular audits with cooperation between central and state governments.
2 chart - hta and pmprb comparison april 7 2020 webinar
Chart created by: Louise Binder & Antonella Scali
The Patients Redefining Healthcare Summit co-hosts, in partnership with the Indigenous Advisory Committee, invite you to join us as we discuss six case studies of oncology drugs analyzed by a health economist based on the proposed PMPRB guidelines. The results and the implications for accessing drugs will be presented. Potential application of this analytical approach in non-oncology areas will also be discussed.
Changing Regulatory Landscape of 2017
In MakroCare whitepaper, we have compiled and simplified some of these new policies, revisions, regulatory amendments from registration, labeling, safety reporting, renewal, publishing /eCTD submission of last year and forthcoming years.
WHO Contribution to impementing MeTA
The role of the World Health Organization (WHO) in the Medicines Transparency Alliance (MeTA), May 2008
PharmacoVigilance Newsletter
Lanzule Limited provides pharmacovigilance services including adverse incident reporting for drugs, devices, and combination products. As of July 2nd 2015, marketing authorization holders must have a Pharmacovigilance System Master File in place to document their pharmacovigilance system and compliance. This applies to products authorized through centralized or non-centralized procedures. Manufacturers of medical devices and mobile medical apps must also have a vigilance system. Lanzule can help collect safety information and report adverse drug reactions electronically or on paper to regulatory authorities.
Background to the Falsified Medicines Directive and the Delegated Regulation
The document discusses the Falsified Medicines Directive and Delegated Regulation, which aim to secure the pharmaceutical supply chain and reduce counterfeit medicines. It outlines key aspects of the new regulations, including unique identifiers and tamper-evident packaging for prescription medicines. Verification of authenticity will occur at wholesale distributors and dispensing points. National repositories will store product information to enable verification. Implementation poses scale and connectivity challenges across the complex supply chain. Wider benefits may include improved patient safety, monitoring, and reducing fraud. Flexibilities allow country-specific requirements and earlier verification in some settings like hospitals.
Former government proposed models
The document outlines several past and proposed models for a national pharmacare program in Canada, including:
1. The 2003 First Ministers Health Accord and National Pharmaceuticals Strategy proposed universal coverage with two options for income-based cost sharing thresholds but negotiations failed.
2. The 2002 Kirby and Romanow reports recommended a $1500 annual catastrophic drug coverage threshold but their recommendations did not move forward.
3. The 2009 Canadian Treatment Action Council model proposed a universal catastrophic drug plan with income-based cost sharing, centralized management, and funding from governments, employers, and manufacturers.
Medicines Transparency Kyrgyzstan
Kyrgyzstan faces several issues related to access to medicines, including limited affordability and availability, especially of medicines for chronic diseases. There is also a problem with low quality medicines entering the country through informal channels. The MeTA program in Kyrgyzstan aims to address these issues by improving information sharing between organizations, disseminating information to the public, and encouraging collaboration between the government, private sector, and civil society organizations.
ATA Praises VA's Commitment to Telemedicine
A graduate of New York Medical College, Dr. Peter Killcommons has spent the past 25 years serving as the CEO of Medweb, a leading telemedicine platform. To stay at the forefront of industry trends, Peter Killcommons maintains membership in the American Telemedicine Association (ATA).
Update on Reforms to the Regulatory Framework for Complementary Medicines
The document summarizes updates on reforms to Australia's regulatory framework for complementary medicines following recommendations from a 2015 review. Key points include:
- Reforms will be implemented over 12-24 months across five streams, including enhancing the listing framework, increasing flexibility for sponsors, improving transparency, predictability for industry, and post-market monitoring.
- Changes involve a permitted indications list, three assessment pathways for medicines, use of international evaluation reports, legislative timeframes, and incentives for innovation.
- Consultations are being held on proposals regarding new assessment pathways, acceptable evidence sources, timeframes and fees, and compliance monitoring. The reforms aim to improve regulation while providing flexibility.
Balkan pharma markets
Short overview on “big5” Pharma markets on Balkan. What is the market structure, what is the share of Generics and how much OTC share takes? Where is the potential of each and what can be expected?
Telepharmacy
Telepharmacy is the delivery of pharmaceutical care via telecommunications to patients in locations where they may not have direct contact with a pharmacist.
seminar presentation
Mutual registration of vaccines in East Africa: Progress and issues for bette...
The 2018 Open Session of the EuFMD Standing Technical Committee was held in Borgo Egnazia - Italy, 29-31 October 2018 . The session theme was on global vaccine security
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
Infusion Pump Shortages
The COVID-19 pandemic has caused mass shortages of ventilators and PPE globally, but now healthcare workers are starting to see the effects of the pandemic on supplies of infusion pumps. Hospitals are starting to see their supply of infusion pumps, which are critical in providing medications and fluids, start to dwindle...
Coronavirus & COVID-19 Update
Commercial health plans and PBMs are responding to the coronavirus pandemic by offering extended prescription supplies, waived copays, and early refills. They are also allowing mail order prescriptions in some cases and supporting cross-state licensing of pharmacy staff. The DEA has agreed to allow controlled substances to be prescribed via telemedicine without an initial in-person visit during the public health emergency. However, state rules and the medical purpose of the prescription still apply. Payment and reimbursement issues may arise regarding prescriptions for anti-malarial drugs prescribed for COVID-19 treatment, as their use for this purpose is still investigational. Pharmacies may face auditing and recoupment later for invalid prescriptions issued during
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
The document discusses the ACSS Consortium's Generic Medicines Work-Sharing Trial (GMWST). It summarizes that the ACSS Consortium allows four regulatory authorities to collaborate on reviews of generic medicines applications. The GMWST aims to complete reviews in 5 months by having one agency lead and others participate. The document describes the first application submitted under the GMWST, noting it took longer than expected but was still faster than individual reviews. It concludes the trial was successful overall and recommends expanding the program to more applications and agencies going forward.
Obra
The Omnibus Budget Reconciliation Act of 1990 (OBRA 90) mandates that state Medicaid programs perform retrospective and prospective drug utilization reviews to evaluate prescribed medications and ensure appropriate usage. It also requires state pharmacy boards to develop educational programs for pharmacists on drug utilization review. Additionally, OBRA 90 states that pharmacists must offer counseling to Medicaid patients and document any counseling provided.
FDA’s Electronic Premarket Submissions Pilot Program
The US FDA’s Center for Devices and Radiological Health (CDRH) announced a new pilot program that will allow the industry to submit premarket submissions electronically during the COVID-19 health emergency.
The Electronic Delivery of Premarket Submissions Pilot Program’s objective is to test CDRH’s capabilities to receive pre-market submissions using BOX, which is a cloud-based sharing service. CDRH began accepting participants for this pilot on October 6th,2020 and the program is intended to last 90 days during the COVID-19 pandemic...
THERAPEUTIC GOODS ADMINSTRATION
Therapeutics Goods Administration(TGA) is a unit of the Australian Government Department of Health and Ageing, is responsible for administering the act.
Private sector engagement for advancing universal health coverage
Private sector engagement for advancing universal health coverageWHO Regional Office for the Eastern Mediterranean
This document discusses private sector engagement in health care in Eastern Mediterranean countries to advance universal health coverage. It finds that out-of-pocket health expenditures are highest in the poorest countries. While private health workforces are concentrated in urban areas, data on their distribution, salaries, and multiple job holding is limited. Utilization of private clinics is highest among the richest populations in countries like Pakistan, Egypt, Morocco, and Jordan. Ministries of Health lack clear vision and strategy toward private sector partnerships and have weak regulatory capacity due to inadequate information collection. Moving forward, reliable information gathering, effective engagement, strategy development and capacity building are needed to further develop private sector involvement and advance universal health coverage in the region.Pharmaceutical regulatory & healthcare laws
The document discusses pharmaceutical regulatory and healthcare laws in Pakistan. It outlines several key organizations that regulate the pharmaceutical industry, including the Drug Regulatory Authority of Pakistan (DRAP). It also summarizes various federal and provincial regulations related to drugs, healthcare facilities, and medical devices. Finally, it provides an overview of international pharmaceutical guidelines from organizations like the International Council for Harmonisation (ICH).
Implementation of wto decisions on trips and public health in comesa drug reg...
Drugs, Drug regulation, Regulatory authorities, test data, WTO Decisions on TRIPS and Public Health, COMESA
MDSAP Reports for EU Surveillance Audits
The Medical Device Single Audit Program covers the compliance requirements of the USA, Brazil, Japan, Canada, and Australia. Although this program does not cover the requirements of the EU, which is the EU MDR and IVDR, a guidance document released by the MDCG (Medical Device Coordination Group) explains the use of MDSAP audit reports by the notified bodies when performing surveillance audits under the EU MDR and IVDR...
Aegate Symposium Frankfurt June 2015 - Graham day 1_fmd
This document discusses the Falsified Medicines Directive (FMD) in the European Union. It provides details on the following key points:
1. The FMD requires medicines at risk of falsification to have unique codes and tamper-evident packaging to enable verification of authenticity.
2. Implementation requirements are being determined through Delegated Acts, which will specify uniform rules across all EU member states.
3. The Delegated Acts are expected to be adopted in August 2015 and published by the end of 2015, giving member states three years to implement safety features and authentication systems.
A Report from ATA
The document summarizes federal and state policy issues and activities related to telemedicine. It discusses 3 easy fixes for CMS policy, other CMS activities, rulemakings by the FCC and FDA, and potential federal legislation. It also covers state Medicaid policy, initiatives, and licensure issues. Finally, it lists ATA activities like meetings and member networks, as well as developing practice guidelines and identifying market changes.
The Importance of Drug Take-back Programs: Protecting our Health and Environment
This template PowerPoint presentation can be used and customized to promote drug take-back in your community. Drug take-back programs (collection receptacles and mail-back envelopes) protect local communities against the environmental and public health impacts of leftover drugs.
Telepharmacy
Telepharmacy allows for the delivery of pharmaceutical care via telecommunication to patients in remote locations without direct access to a pharmacist. It involves a central pharmacy using audio/video technology to provide clinical services like counseling to remote sites staffed by technicians. The document discusses different telepharmacy models used in various countries and states how it works through the central pharmacy verifying prescriptions and remotely monitoring medication dispensing. While it improves access to care, challenges include ensuring compliance with pharmacy laws and providing continuous care through technology.
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingCanadian Organization for Rare Disorders
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.Guidance for industry cmc postapproval manufacturing changes to be documented...
This guidance from the FDA provides recommendations to drug application holders regarding CMC post-approval manufacturing changes that should be documented in annual reports rather than submitted as supplements. It includes appendices listing examples of changes that generally have a minimal potential effect on product quality, such as equipment additions or minor manufacturing process changes. The guidance aims to clarify reporting requirements, better allocate FDA resources, and implement a risk-based approach to CMC regulation as recommended in the FDA's Pharmaceutical Quality Initiative.
More Related Content
What's hot
Medicines Transparency Kyrgyzstan
Kyrgyzstan faces several issues related to access to medicines, including limited affordability and availability, especially of medicines for chronic diseases. There is also a problem with low quality medicines entering the country through informal channels. The MeTA program in Kyrgyzstan aims to address these issues by improving information sharing between organizations, disseminating information to the public, and encouraging collaboration between the government, private sector, and civil society organizations.
ATA Praises VA's Commitment to Telemedicine
A graduate of New York Medical College, Dr. Peter Killcommons has spent the past 25 years serving as the CEO of Medweb, a leading telemedicine platform. To stay at the forefront of industry trends, Peter Killcommons maintains membership in the American Telemedicine Association (ATA).
Update on Reforms to the Regulatory Framework for Complementary Medicines
The document summarizes updates on reforms to Australia's regulatory framework for complementary medicines following recommendations from a 2015 review. Key points include:
- Reforms will be implemented over 12-24 months across five streams, including enhancing the listing framework, increasing flexibility for sponsors, improving transparency, predictability for industry, and post-market monitoring.
- Changes involve a permitted indications list, three assessment pathways for medicines, use of international evaluation reports, legislative timeframes, and incentives for innovation.
- Consultations are being held on proposals regarding new assessment pathways, acceptable evidence sources, timeframes and fees, and compliance monitoring. The reforms aim to improve regulation while providing flexibility.
Balkan pharma markets
Short overview on “big5” Pharma markets on Balkan. What is the market structure, what is the share of Generics and how much OTC share takes? Where is the potential of each and what can be expected?
Telepharmacy
Telepharmacy is the delivery of pharmaceutical care via telecommunications to patients in locations where they may not have direct contact with a pharmacist.
seminar presentation
Mutual registration of vaccines in East Africa: Progress and issues for bette...
The 2018 Open Session of the EuFMD Standing Technical Committee was held in Borgo Egnazia - Italy, 29-31 October 2018 . The session theme was on global vaccine security
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
Infusion Pump Shortages
The COVID-19 pandemic has caused mass shortages of ventilators and PPE globally, but now healthcare workers are starting to see the effects of the pandemic on supplies of infusion pumps. Hospitals are starting to see their supply of infusion pumps, which are critical in providing medications and fluids, start to dwindle...
Coronavirus & COVID-19 Update
Commercial health plans and PBMs are responding to the coronavirus pandemic by offering extended prescription supplies, waived copays, and early refills. They are also allowing mail order prescriptions in some cases and supporting cross-state licensing of pharmacy staff. The DEA has agreed to allow controlled substances to be prescribed via telemedicine without an initial in-person visit during the public health emergency. However, state rules and the medical purpose of the prescription still apply. Payment and reimbursement issues may arise regarding prescriptions for anti-malarial drugs prescribed for COVID-19 treatment, as their use for this purpose is still investigational. Pharmacies may face auditing and recoupment later for invalid prescriptions issued during
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
The document discusses the ACSS Consortium's Generic Medicines Work-Sharing Trial (GMWST). It summarizes that the ACSS Consortium allows four regulatory authorities to collaborate on reviews of generic medicines applications. The GMWST aims to complete reviews in 5 months by having one agency lead and others participate. The document describes the first application submitted under the GMWST, noting it took longer than expected but was still faster than individual reviews. It concludes the trial was successful overall and recommends expanding the program to more applications and agencies going forward.
Obra
The Omnibus Budget Reconciliation Act of 1990 (OBRA 90) mandates that state Medicaid programs perform retrospective and prospective drug utilization reviews to evaluate prescribed medications and ensure appropriate usage. It also requires state pharmacy boards to develop educational programs for pharmacists on drug utilization review. Additionally, OBRA 90 states that pharmacists must offer counseling to Medicaid patients and document any counseling provided.
FDA’s Electronic Premarket Submissions Pilot Program
The US FDA’s Center for Devices and Radiological Health (CDRH) announced a new pilot program that will allow the industry to submit premarket submissions electronically during the COVID-19 health emergency.
The Electronic Delivery of Premarket Submissions Pilot Program’s objective is to test CDRH’s capabilities to receive pre-market submissions using BOX, which is a cloud-based sharing service. CDRH began accepting participants for this pilot on October 6th,2020 and the program is intended to last 90 days during the COVID-19 pandemic...
THERAPEUTIC GOODS ADMINSTRATION
Therapeutics Goods Administration(TGA) is a unit of the Australian Government Department of Health and Ageing, is responsible for administering the act.
Private sector engagement for advancing universal health coverage
Private sector engagement for advancing universal health coverageWHO Regional Office for the Eastern Mediterranean
This document discusses private sector engagement in health care in Eastern Mediterranean countries to advance universal health coverage. It finds that out-of-pocket health expenditures are highest in the poorest countries. While private health workforces are concentrated in urban areas, data on their distribution, salaries, and multiple job holding is limited. Utilization of private clinics is highest among the richest populations in countries like Pakistan, Egypt, Morocco, and Jordan. Ministries of Health lack clear vision and strategy toward private sector partnerships and have weak regulatory capacity due to inadequate information collection. Moving forward, reliable information gathering, effective engagement, strategy development and capacity building are needed to further develop private sector involvement and advance universal health coverage in the region.Pharmaceutical regulatory & healthcare laws
The document discusses pharmaceutical regulatory and healthcare laws in Pakistan. It outlines several key organizations that regulate the pharmaceutical industry, including the Drug Regulatory Authority of Pakistan (DRAP). It also summarizes various federal and provincial regulations related to drugs, healthcare facilities, and medical devices. Finally, it provides an overview of international pharmaceutical guidelines from organizations like the International Council for Harmonisation (ICH).
Implementation of wto decisions on trips and public health in comesa drug reg...
Drugs, Drug regulation, Regulatory authorities, test data, WTO Decisions on TRIPS and Public Health, COMESA
MDSAP Reports for EU Surveillance Audits
The Medical Device Single Audit Program covers the compliance requirements of the USA, Brazil, Japan, Canada, and Australia. Although this program does not cover the requirements of the EU, which is the EU MDR and IVDR, a guidance document released by the MDCG (Medical Device Coordination Group) explains the use of MDSAP audit reports by the notified bodies when performing surveillance audits under the EU MDR and IVDR...
Aegate Symposium Frankfurt June 2015 - Graham day 1_fmd
This document discusses the Falsified Medicines Directive (FMD) in the European Union. It provides details on the following key points:
1. The FMD requires medicines at risk of falsification to have unique codes and tamper-evident packaging to enable verification of authenticity.
2. Implementation requirements are being determined through Delegated Acts, which will specify uniform rules across all EU member states.
3. The Delegated Acts are expected to be adopted in August 2015 and published by the end of 2015, giving member states three years to implement safety features and authentication systems.
A Report from ATA
The document summarizes federal and state policy issues and activities related to telemedicine. It discusses 3 easy fixes for CMS policy, other CMS activities, rulemakings by the FCC and FDA, and potential federal legislation. It also covers state Medicaid policy, initiatives, and licensure issues. Finally, it lists ATA activities like meetings and member networks, as well as developing practice guidelines and identifying market changes.
The Importance of Drug Take-back Programs: Protecting our Health and Environment
This template PowerPoint presentation can be used and customized to promote drug take-back in your community. Drug take-back programs (collection receptacles and mail-back envelopes) protect local communities against the environmental and public health impacts of leftover drugs.
Telepharmacy
Telepharmacy allows for the delivery of pharmaceutical care via telecommunication to patients in remote locations without direct access to a pharmacist. It involves a central pharmacy using audio/video technology to provide clinical services like counseling to remote sites staffed by technicians. The document discusses different telepharmacy models used in various countries and states how it works through the central pharmacy verifying prescriptions and remotely monitoring medication dispensing. While it improves access to care, challenges include ensuring compliance with pharmacy laws and providing continuous care through technology.
What's hot (20)
Update on Reforms to the Regulatory Framework for Complementary Medicines
Update on Reforms to the Regulatory Framework for Complementary Medicines
Mutual registration of vaccines in East Africa: Progress and issues for bette...
Mutual registration of vaccines in East Africa: Progress and issues for bette...
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
FDA’s Electronic Premarket Submissions Pilot Program
FDA’s Electronic Premarket Submissions Pilot Program
Private sector engagement for advancing universal health coverage
Private sector engagement for advancing universal health coverage
Implementation of wto decisions on trips and public health in comesa drug reg...
Implementation of wto decisions on trips and public health in comesa drug reg...
Aegate Symposium Frankfurt June 2015 - Graham day 1_fmd
Aegate Symposium Frankfurt June 2015 - Graham day 1_fmd
The Importance of Drug Take-back Programs: Protecting our Health and Environment
The Importance of Drug Take-back Programs: Protecting our Health and Environment
Similar to 4 pmprb webinar recommendations louise binder april 7 2020
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingCanadian Organization for Rare Disorders
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.Guidance for industry cmc postapproval manufacturing changes to be documented...
This guidance from the FDA provides recommendations to drug application holders regarding CMC post-approval manufacturing changes that should be documented in annual reports rather than submitted as supplements. It includes appendices listing examples of changes that generally have a minimal potential effect on product quality, such as equipment additions or minor manufacturing process changes. The guidance aims to clarify reporting requirements, better allocate FDA resources, and implement a risk-based approach to CMC regulation as recommended in the FDA's Pharmaceutical Quality Initiative.
Webinar 3: Bringing Home the 5% Solution
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
Canada Telemedicine Market Analysis Sample Report
With the advent of advanced technologies like machine learning, artificial intelligence, and the Internet of things in Canada, the Canadian telemedicine market is expected to grow from $4.86 Bn in 2022 to $18.53 Bn in 2030 with a CAGR of 18.2% for the year 2022-2030. The market is segmented by products and services, end users, and delivery mode. To get a detailed report, contact us at - info@insights10.com
Canada Clinical Diagnostics Market
Canada's clinical diagnostics is expected to witness significant growth from $3.9 Bn in 2022 to $4.9 Bn in 2030 with a CAGR of 3.1% for the year 2022-30. The main growth drivers of the Canadian clinical diagnostics market are growing awareness about early disease detection and the benefits of early treatment. Further, the increasing investments by the government in diagnostic services are responsible for the market growth.To get a detailed report, contact us at - info@insights10.com
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
The document discusses recent developments regarding product listing agreements (PLAs) with the pan-Canadian Pharmaceutical Alliance (pCPA) and private payers in Canada. It notes that the pCPA office is now operational, which could standardize and improve the negotiation process. It also discusses Quebec recently joining pCPA negotiations, which may lead to more products being listed faster in that province. The document also examines the growing interest of private payers in Canada in negotiating their own PLAs, especially for specialty products, and finds that these agreements will likely become more important and prevalent over time.
UAE Nutritional Supplements Market Analysis Sample Report
By 2030, it is anticipated that the UAE nutrition and supplements market will reach a value of $3.94 Bn from $1.91 Bn in 2022, growing at a CAGR of 9.5% during 2022-30. The market is primarily dominated by local players such as Vitabiotics Ltd, Bayer Middle East, and Forever Living Products. To get a detailed report, contact us at - info@insights10.com
Canada Clinical Diagnostics Market Sample Report 2022 to 2030
Canada's clinical diagnostics is expected to witness significant growth from $3.9 Bn in 2022 to $4.9 Bn in 2030 with a CAGR of 3.1% for the year 2022-30.
New EU PV regulations
This document summarizes the major changes brought about by the new European Union pharmacovigilance legislation. It overviews the goals of improving safety monitoring and decision making. Key changes include new guidelines on pharmacovigilance systems and risk management, the establishment of the Pharmacovigilance Risk Assessment Committee, more stringent reporting rules, and increased transparency including public access to safety information. The legislation aims to modernize the EU pharmacovigilance system and better protect public health.
RDD 2020 Day 1 AM - Durhane Wong-Rieger
Rare Disease Day Conference 2020 Day 1- Durhane Wong-Rieger
A ROADMAP for Access to Drugs for Rare Diseases in Canada?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Canadian Organization for Rare Disorders
CORD Spring 2020 Webinar Series
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Ucm358301
This document provides guidance on four FDA programs that aim to expedite development and review of new drugs to treat serious or life-threatening conditions with unmet medical need. The four programs are: fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. The guidance describes the qualifying criteria and features of each program, and provides an overview of general considerations for manufacturing, nonclinical studies, clinical inspections, and companion diagnostics. It aims to serve as a single resource on the policies and procedures for these expedited programs.
PhillyCooke eCTD Submissions for Ad-Promo
This presentation was initially delivered at the NJ/NY RAPS chapter on November 19, 2015. It reviews the FDA guidance on providing ad-promo submissions in electronic and print formats, explains the complex nature of the guidance and its scope, and includes the latest from FDA on how the guidance is being implemented.
China Pharmaceuticals - Building bridges to innovation - BioCentury China He...
This document provides a summary of a McKinsey & Company presentation on the pharmaceutical market in China. It discusses key growth drivers for China's pharmaceutical market, increasing contributions of China to global sales for major pharmaceutical companies, and new commercial models and investments by pharmaceutical companies in China. It also summarizes recent trends impacting the Chinese market such as emerging new commercial models, increasing role of private capital and IT companies, rising quality and innovation among domestic Chinese players, and proposed changes to China's drug reimbursement and pricing policies.
Ucm072331
This document provides guidance for submitting regulatory information to the FDA in electronic format, specifically focusing on the content of labeling. It outlines that the FDA is transitioning to accepting content of labeling using the Structured Product Labeling (SPL) standard to make the information easier to process, review and exchange between systems. SPL allows labeling information to be submitted in XML format, enabling uses like populating electronic health records and supporting electronic prescribing initiatives. The guidance provides details on file formats, procedures and organizing electronic submissions using SPL.
Good anda submission practices
This document provides guidance for industry on good abbreviated new drug application (ANDA) submission practices to avoid common deficiencies that can lead to delays in approval. It highlights issues that frequently result in multiple review cycles, including deficiencies related to patents and exclusivity, labeling, product quality, bioequivalence data, and facilities. The guidance aims to help applicants submit more complete applications in order to streamline the ANDA review process.
Cipla Q3 2024 Presentation at Nuvama.pdf
The document summarizes an upcoming conference in 2024 hosted by Nuvama India. It lists the Global Chief Financial Officer, Ashish Adukia and Global Chief Strategy Officer, Jasdeep Singh as speakers. It provides various disclaimers related to forward-looking statements, medical information, and product recommendations. The agenda outlines topics on Cipla's way forward, trends in India, and Cipla's journey so far.
UNITAID Operations Report to EB12
This report was presented to the 12th session of the Executive Board, on 9 June 2010. It contains the most recent data on the performance of Operations Unit, including an overview of the HIV/AIDS, malaria and tuberculosis portfolio.
Ucm072331
This document provides guidance for submitting regulatory submissions of content of labeling to the FDA in electronic format using Structured Product Labeling (SPL), an XML-based standard. It outlines that SPL allows for more efficient exchange and review of labeling information compared to PDF. It describes how to create SPL files according to HL7 specifications and submit them to the FDA either before or after implementation of an automated system for processing SPL files.
Similar to 4 pmprb webinar recommendations louise binder april 7 2020 (20)
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Guidance for industry cmc postapproval manufacturing changes to be documented...
Guidance for industry cmc postapproval manufacturing changes to be documented...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
UAE Nutritional Supplements Market Analysis Sample Report
UAE Nutritional Supplements Market Analysis Sample Report
Canada Clinical Diagnostics Market Sample Report 2022 to 2030
Canada Clinical Diagnostics Market Sample Report 2022 to 2030
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
China Pharmaceuticals - Building bridges to innovation - BioCentury China He...
China Pharmaceuticals - Building bridges to innovation - BioCentury China He...
More from Natalie Richardson
4 pmprb recommendations french april 7 2020 webinar louise binder
Les organisateurs du Sommet sur la redéfinition des soins de santé par les patients, en partenariat avec le Comité consultatif autochtone, vous invitent à vous joindre à nous pour une discussion de six études de cas sur des médicaments oncologiques tels qu’analysés par un économiste de la santé sur la base des lignes directrices actuellement proposées par la Conseil d’examen du prix des médicaments brevetés (CEPMB). Seront présentés les résultats de l’étude et leurs implications sur l’accès aux médicaments. On discutera aussi de l’application possible de cette approche analytique à des domaines non oncologiques.
2 pmprb webinar april 7 2020 french hta and pmprb comparison chart
Les organisateurs du Sommet sur la redéfinition des soins de santé par les patients, en partenariat avec le Comité consultatif autochtone, vous invitent à vous joindre à nous pour une discussion de six études de cas sur des médicaments oncologiques tels qu’analysés par un économiste de la santé sur la base des lignes directrices actuellement proposées par la Conseil d’examen du prix des médicaments brevetés (CEPMB). Seront présentés les résultats de l’étude et leurs implications sur l’accès aux médicaments. On discutera aussi de l’application possible de cette approche analytique à des domaines non oncologiques.
3 pmprb webinar april 7 2020 french guidelines case studies matthew brougham
Les organisateurs du Sommet sur la redéfinition des soins de santé par les patients, en partenariat avec le Comité consultatif autochtone, vous invitent à vous joindre à nous pour une discussion de six études de cas sur des médicaments oncologiques tels qu’analysés par un économiste de la santé sur la base des lignes directrices actuellement proposées par la Conseil d’examen du prix des médicaments brevetés (CEPMB). Seront présentés les résultats de l’étude et leurs implications sur l’accès aux médicaments. On discutera aussi de l’application possible de cette approche analytique à des domaines non oncologiques.
1 pmprb webinar french april 7 2020 wayne critchley
Les organisateurs du Sommet sur la redéfinition des soins de santé par les patients, en partenariat avec le Comité consultatif autochtone, vous invitent à vous joindre à nous pour une discussion de six études de cas sur des médicaments oncologiques tels qu’analysés par un économiste de la santé sur la base des lignes directrices actuellement proposées par la Conseil d’examen du prix des médicaments brevetés (CEPMB). Seront présentés les résultats de l’étude et leurs implications sur l’accès aux médicaments. On discutera aussi de l’application possible de cette approche analytique à des domaines non oncologiques.
3 pmprb guidelines case studies presentation april 7 2020 mb
This document analyzes how several new oncology drugs recently approved in Canada would fare under the proposed new PMPRB guidelines. It estimates the maximum rebated price (MRP) that each drug could expect to receive and whether the drug would still launch in Canada at that price. Drugs like venetoclax, daratumumab, blinatumomab and osimertinib would likely require price reductions of over 80% to reach the MRP, making their availability in Canada very unlikely. Nivolumab and dinutuximab could launch with smaller price adjustments of 25% or less. The analysis identifies assumptions made and limitations in using CADTH reports to fully estimate prices under the new guidelines.
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
This document provides an overview of Merkel cell carcinoma, including its histogenesis, pathogenesis, epidemiology, clinical features, diagnosis, staging, treatment options for both localized and metastatic disease, and prognosis. Key points discussed are the role of Merkel cell polyomavirus in pathogenesis, increasing incidence with age and sun exposure, diagnosis through biopsy and immunohistochemistry, standard treatment involving surgery and/or radiation for localized disease and chemotherapy or immunotherapy for advanced stages, and generally poor prognosis especially for metastatic or recurrent disease.
Biosimilars Presentation - Save Your Skin Foundation
Presentation about Biosimilars on Save Your Skin Foundation webinar, January 19, 2018. This is presentation #3 of 3 in the webinar: 1. Health Canada 2. CADTH 3. Louise Binder, Save Your Skin Fdn.
Biosimilars Presentation - CADTH
Presentation about Biosimilars on Save Your Skin Foundation webinar, January 19, 2018. This is presentation #2 of 3 in the webinar: 1. Health Canada 2. CADTH 3. Louise Binder, Save Your Skin Fdn.
Biosimilars Presentation - Health Canada
Presentation about Biosimilars on Save Your Skin Foundation webinar, January 19, 2018. This is presentation #1 of 3 in the webinar: 1. Health Canada 2. CADTH 3. Louise Binder, Save Your Skin Fdn.
More from Natalie Richardson (9)
4 pmprb recommendations french april 7 2020 webinar louise binder
4 pmprb recommendations french april 7 2020 webinar louise binder
2 pmprb webinar april 7 2020 french hta and pmprb comparison chart
2 pmprb webinar april 7 2020 french hta and pmprb comparison chart
3 pmprb webinar april 7 2020 french guidelines case studies matthew brougham
3 pmprb webinar april 7 2020 french guidelines case studies matthew brougham
1 pmprb webinar french april 7 2020 wayne critchley
1 pmprb webinar french april 7 2020 wayne critchley
3 pmprb guidelines case studies presentation april 7 2020 mb
3 pmprb guidelines case studies presentation april 7 2020 mb
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar)
Biosimilars Presentation - Save Your Skin Foundation
Biosimilars Presentation - Save Your Skin Foundation
Recently uploaded
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa Ajman
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa AjmanMalayali Kerala Spa Ajman
Our Spa Massage Center Ajman prioritizes efficiency to ensure a satisfying massage experience for our clients at Malayali Kerala Spa Ajman. We offer a hassle-free appointment system, effective health issue identification, and precise massage techniques.
Our Spa in Ajman stands out for its effectiveness in enhancing wellness. Our therapists focus on treating the root cause of issues, providing tailored treatments for each client. We take pride in offering the most satisfying Pakistani Spa service, adjusting treatment plans based on client feedback.
For the most result-oriented Russian Spa treatment in Ajman, visit our Massage Center. Our Russian therapists are skilled in various techniques to address health concerns. Our body-to-body massage is efficient due to individualized care and high-grade massage oils.Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson educationEnglish Drug and Alcohol Commissioners June 2024.pptx
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
UoA毕业证学历书【微信95270640】办文凭{昆士兰科技大学毕业证}Q微Q微信95270640UoA毕业证书成绩单/学历认证UoA Diploma未毕业、挂科怎么办？+QQ微信：Q微信95270640-大学Offer（申请大学）、成绩单（申请考研）、语言证书、在读证明、使馆公证、办真实留信网认证、真实大使馆认证、学历认证
办理国外昆士兰科技大学毕业证书 #成绩单改成绩 #教育部学历学位认证 #毕业证认证 #留服认证 #使馆认证（留学回国人员证明） #（证）等
真实教育部认证教育部存档中国教育部留学服务中心认证（即教育部留服认证）网站100%可查.
真实使馆认证（即留学人员回国证明）使馆存档可通过大使馆查询确认.
留信网认证国家专业人才认证中心颁发入库证书留信网永久存档可查.
昆士兰科技大学昆士兰科技大学毕业证文凭证书毕业证 #成绩单等全套材料从防伪到印刷从水印到钢印烫金跟学校原版100%相同.
国际留学归国服务中心：实体公司注册经营行业标杆精益求精！
国外毕业证学位证成绩单办理流程：
1客户提供办理昆士兰科技大学昆士兰科技大学毕业证文凭证书信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作昆士兰科技大学毕业证成绩单电子图；
3昆士兰科技大学毕业证成绩单电子版做好以后发送给您确认；
4昆士兰科技大学毕业证成绩单电子版您确认信息无误之后安排制作成品；
5昆士兰科技大学成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快递邮寄昆士兰科技大学昆士兰科技大学毕业证文凭证书）。闷不乐的样子父亲特意带山娃去找三楼房东家的儿子小伍玩小伍比山娃小一岁虎头虎脑的很霸气父亲让山娃跟小伍去夏令营听课山娃很高兴夏令营就设在附近一所小学山娃发现那所小学比自己的学校更大更美操场上还铺有塑胶跑道呢里面很多小朋友一班一班的快快乐乐原来城里娃都藏这儿来了怪不得平时见不到他们山娃恍然大悟起来吹拉弹唱琴棋书画山娃都不懂却什么都想学山娃怨自己太笨什么都不会斟酌再三山娃终于选定了学美术当听说每月要交感
05 CLINICAL AUDIT-ORTHO done at a peripheral.pptx
Clinical audit on pain management done at peripheral health centre
THE SPECIAL SENCES- Unlocking the Wonders of the Special Senses: Sight, Sound...
Title: Unlocking the Wonders of the Special Senses: Sight, Sound, Smell, Taste, and Balance
Introduction:
Welcome to our captivating SlideShare presentation on the Special Senses, where we delve into the extraordinary capabilities that allow us to perceive and interact with the world around us. Join us on a sensory journey as we explore the intricate structures and functions of sight, sound, smell, taste, and balance.
The special senses are our primary means of experiencing and interpreting the environment, each sense providing unique and vital information that shapes our perceptions and responses. These senses are facilitated by highly specialized organs and complex neural pathways, enabling us to see a vibrant sunset, hear a symphony, savor a delicious meal, detect a fragrant flower, and maintain our equilibrium.
In this presentation, we will:
Visual System (Sight): Dive into the anatomy and physiology of the eye, exploring how light is converted into electrical signals and processed by the brain to create the images we see. Understand common vision disorders and the mechanisms behind corrective measures like glasses and contact lenses.
Auditory System (Hearing): Examine the structures of the ear and the process of sound wave transduction, from the outer ear to the cochlea and auditory nerve. Learn about hearing loss, auditory processing, and the advances in hearing aid technology.
Olfactory System (Smell): Discover the olfactory receptors and pathways that enable the detection of thousands of different odors. Explore the connection between smell and memory and the impact of olfactory disorders on quality of life.
Gustatory System (Taste): Uncover the taste buds and the five basic tastes – sweet, salty, sour, bitter, and umami. Delve into the interplay between taste and smell and the factors influencing our food preferences and eating habits.
Vestibular System (Balance): Investigate the inner ear structures responsible for balance and spatial orientation. Understand how the vestibular system helps maintain posture and coordination, and explore common vestibular disorders and their effects.
Through engaging visuals, interactive diagrams, and insightful explanations, we aim to illuminate the complexities of the special senses and their profound impact on our daily lives. Whether you're a student, educator, or simply curious about how we perceive the world, this presentation will provide valuable insights into the remarkable capabilities of the human sensory system.
Join us as we unlock the wonders of the special senses and gain a deeper appreciation for the intricate mechanisms that allow us to experience the richness of our environment.
一比一原版布里斯托大学毕业证(Bristol毕业证书)学历如何办理
补办文凭【微信号:176555708】【(Bristol毕业证书)】【微信号:176555708】《成绩单、外壳、offer、真实留信官方学历认证（永久存档/真实可查）》采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路）我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信号:176555708】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信号:176555708】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Sexual Disorders.gender identity disorderspptx
Gender identity disorder, paraphilias , sexual dysfunction
Research, Monitoring and Evaluation, in Public Health
This is a presentation on the overview of the role of monitoring and evaluation in public health. It describes the various components and how a robust M&E system can possitively impact the results or effectiveness of a public health intervention.
Test bank advanced health assessment and differential diagnosis essentials fo...
Test bank advanced health assessment and differential diagnosis essentials fo...rightmanforbloodline
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.nursing management of patient with Empyema ppt
prepared by Prof. BLESSY THOMAS, SPN
Empyema is a disease of respiratory system It is defines as the accumulation of thick, purulent fluid within the pleural space, often with fibrin development.
Empyema is also called pyothorax or purulent pleuritis.
It’s a condition in which pus gathers in the area between the lungs and the inner surface of the chest wall. This area is known as the pleural space.
Pus is a fluid that’s filled with immune cells, dead cells, and bacteria.
Pus in the pleural space can’t be coughed out. Instead, it needs to be drained by a needle or surgery.
Empyema usually develops after pneumonia, which is an infection of the lung tissue. it is mainly caused due in infectious micro-organisms. It can be treated with medications and other measures.
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPT
Prepared by Prof. BLESSY THOMAS, VICE PRINCIPAL, FNCON, SPN.
Emphysema is a disease condition of respiratory system.
Emphysema is an abnormal permanent enlargement of the air spaces distal to terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.
Emphysema of lung is defined as hyper inflation of the lung ais spaces due to obstruction of non respiratory bronchioles as due to loss of elasticity of alveoli.
It is a type of chronic obstructive
pulmonary disease.
It is a progressive disease of lungs.
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Know Latest Hiranandani Hospital Powai News.pdf
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
Health Tech Market Intelligence Prelim Questions -
The Ultimate Guide to Setting up Market Research in Health Tech part -1
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
This lays foundation of scoping research project what are the
Before embarking on a research project, especially one aimed at scoping and defining parameters like the one described for health tech IT, several crucial considerations should be addressed. Here’s a comprehensive guide covering key aspects to ensure a well-structured and successful research initiative:
1. Define Research Objectives and Scope
Clear Objectives: Define specific goals such as understanding market needs, identifying new opportunities, assessing risks, or refining pricing strategies.
Scope Definition: Clearly outline the boundaries of the research in terms of geographical focus, target demographics (e.g., age, socio-economic status), and industry sectors (e.g., healthcare IT).
3. Review Existing Literature and Resources
Literature Review: Conduct a thorough review of existing research, market reports, and relevant literature to build foundational knowledge.
Gap Analysis: Identify gaps in existing knowledge or areas where further exploration is needed.
4. Select Research Methodology and Tools
Methodological Approach: Choose appropriate research methods such as surveys, interviews, focus groups, or data analytics.
Tools and Resources: Select tools like Google Forms for surveys, analytics platforms (e.g., SimilarWeb, Statista), and expert consultations.
5. Ethical Considerations and Compliance
Ethical Approval: Ensure compliance with ethical guidelines for research involving human subjects.
Data Privacy: Implement measures to protect participant confidentiality and adhere to data protection regulations (e.g., GDPR, HIPAA).
6. Budget and Resource Allocation
Resource Planning: Allocate resources including time, budget, and personnel required for each phase of the research.
Contingency Planning: Anticipate and plan for unforeseen challenges or adjustments to the research plan.
7. Develop Research Instruments
Survey Design: Create well-structured surveys using tools like Google Forms to gather quantitative data.
Interview and Focus Group Guides: Prepare detailed scripts and discussion points for qualitative data collection.
8. Sampling Strategy
Sampling Design: Define the sampling frame, size, and method (e.g., random sampling, stratified sampling) to ensure representation of target demographics.
Participant Recruitment: Plan recruitment strategies to reach and engage the intended participant groups effectively.
9. Data Collection and Analysis Plan
Data Collection: Implement methods for data gathering, ensuring consistency and validity.
Analysis Techniques: Decide on analytical approaches (e.g., statistical
National Rural Health Mission(NRHM).pptx
This document describes the NRHM Scheme, its goals, objectives, components, and new initiatives.
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...rightmanforbloodline
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressedRecently uploaded (20)
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa Ajman
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa Ajman
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...
English Drug and Alcohol Commissioners June 2024.pptx
English Drug and Alcohol Commissioners June 2024.pptx
THE SPECIAL SENCES- Unlocking the Wonders of the Special Senses: Sight, Sound...
THE SPECIAL SENCES- Unlocking the Wonders of the Special Senses: Sight, Sound...
Research, Monitoring and Evaluation, in Public Health
Research, Monitoring and Evaluation, in Public Health
Test bank advanced health assessment and differential diagnosis essentials fo...
Test bank advanced health assessment and differential diagnosis essentials fo...
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
Health Tech Market Intelligence Prelim Questions -
Health Tech Market Intelligence Prelim Questions -
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Solution manual for managerial accounting 18th edition by ray garrison eric n...
Solution manual for managerial accounting 18th edition by ray garrison eric n...
4 pmprb webinar recommendations louise binder april 7 2020
- 1. Recommendations for PMPRB Guideline from Oncology Groups Presented February 14th, 2020
- 2. Recommendations 1 and 2 Recommendation #1 The Guidelines be amended to adopt explicitly the CADTH pCODR deliberative framework for oncology health technology assessment and remove any specific reference to an ICER. Recommendation #2 The Guidelines be amended to provide that PMPRB’s public decision will provide information that the analysis has either met the PMPRB threshold and is not excessive or that it has not met the PMPRB threshold or other CADTH analysis and is excessive. No specific economic data or numbers supporting this decision will be made public by PMPRB. This will ensure that the public Canadian price will not put at risk the U.S. market such that companies will decline to enter, or delay, the Canadian market for that reason.
- 3. Recommendation 3 Recommendation #3 The Guidelines be amended to provide for ongoing monitoring and evaluation by a multi- stakeholder Committee and a publicly issued annual report of findings of this Committee. At least two patient group representatives chosen by the patient community, with one from the cancer community, will be included.
- 4. Recommendations 4 and 5 Recommendation #4 No Guideline finalization should take place until a full consultation is undertaken with Quebec stakeholders including patient groups and patients with all documents and consultations taking place in both Official languages. Recommendation #5 No Guideline finalization should take place until a full consultation is undertaken with Indigenous stakeholders i.e. First Nations, Metis and Inuit including patient groups and patients following a process of their choosing.